SPYRE THERAPEUTICS, INC. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
SPYRE THERAPEUTICS, INC. (SYRE) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of $700.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-02-19
- SPYRE THERAPEUTICS, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2025 was $700.00K.
- SPYRE THERAPEUTICS, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2024 was -$100.00K.
- SPYRE THERAPEUTICS, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2023 was -$300.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $700.00K 10-K · filed 2026-02-19 | |
| 2024-12-31 | -$100.00K 10-K · filed 2026-02-19 | |
| 2023-12-31 | -$300.00K 10-K · filed 2026-02-19 | $300.00K 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |